LncRNA BE503655 inhibits osteosarcoma cell proliferation, invasion/migration via Wnt/β-catenin pathway

Area of Science:

• Oncology
• Molecular Biology
• Genetics

Background:

• Numerous long non-coding RNAs (lncRNAs) are dysregulated in various cancers, but their specific roles in osteosarcoma are not fully understood.
• Osteosarcoma is a primary bone malignancy with significant metastatic potential, necessitating novel therapeutic targets.

Purpose of the Study:

• To investigate the function and molecular mechanism of lncRNA BE503655 in osteosarcoma.
• To explore the potential of lncRNA BE503655 as a therapeutic target for osteosarcoma.

Main Methods:

• Quantitative real-time PCR and Western blotting were employed to assess lncRNA BE503655 and β-catenin expression.
• Functional assays including Transwell invasion, cell cycle, and proliferation assays were conducted.
• Correlation analysis was performed between BE503655 expression and clinicopathological features.

Main Results:

• lncRNA BE503655 was found to be significantly overexpressed in osteosarcoma tissues and cell lines.
• Knockdown of lncRNA BE503655 inhibited osteosarcoma cell proliferation, invasion, and migration.
• High BE503655 expression correlated with advanced Enneking stage, distant metastasis, and higher histological grade.
• Evidence suggests lncRNA BE503655 exerts its functions through the regulation of the Wnt/β-catenin signaling pathway.

Conclusions:

• lncRNA BE503655 plays a crucial role in promoting osteosarcoma progression.
• The Wnt/β-catenin signaling pathway is involved in the mechanism of lncRNA BE503655 action.
• lncRNA BE503655 represents a potential biomarker and therapeutic target for osteosarcoma.